New safety information from post-market use of MabCampath has been reported and includes serious and sometimes fatal adverse reactions of haemophagocytic lymphohistiocytosis (HLH), stroke (including ischaemic and haemorrhagic stroke), and glomerulonephritis.
Products affected
MabCampath
® (alemtuzumab) 30 mg/mL, 1mL vial
Background information
MabCampath (alemtuzumab) is a monoclonal antibody indicated for the treatment of patients with previously untreated progressive B-cell chronic lymphocytic leukemia (B-CLL). MabCampath is also indicated for the treatment of B-CLL patients who have been treated with alkylating agents and who have failed fludarabine therapy.
Serious and sometimes fatal adverse reactions of haemophagocytic lymphohistiocytosis (HLH), stroke (including ischaemic and haemorrhagic stroke), and glomerulonephritis have been identified from post-market use of MabCampath (alemtuzumab). The risks of HLH, stroke, and glomerulonephritis and related risk minimisation measures have been included in the
Warnings and Precautions and
Post-Market Adverse Drug Reactions sections of the Canadian Product Monograph (CPM) for MabCampath.
In October 2019, Health Canada
communicated safety information for LEMTRADA (alemtuzumab), including risks of haemophagocytic lymphohistiocytosis (HLH), and associated serious cardiovascular reactions, including stroke. LEMTRADA is a drug that contains the same active ingredient, alemtuzumab, as MabCampath, but is used for a different indication, management of multiple sclerosis (MS), and with a different dosing regimen than MabCampath. At the time, Health Canada communicated this safety information associated only with LEMTRADA since the identified risks were not specifically related to MabCampath.
Haemophagocytic lymphohistiocytosis (HLH)
HLH is a life-threatening syndrome of pathologic immune activation characterized clinically by signs and symptoms of extreme systemic inflammation. Symptoms include but are not limited to fever, rash, lymphadenopathy, hepatosplenomegaly and serious hematologic abnormalities. It is associated with high mortality rates if not recognized early and treated promptly. Symptoms have been reported to occur within a few months following the initiation of treatment, and are commonly observed in association with infections.